XOMA (Details Narrative) - USD ($) $ in Thousands			3 Months Ended
XOMA (Details Narrative) - USD ($) $ in Thousands	Jun. 03, 2024	Jun. 21, 2023	Mar. 31, 2024	Mar. 31, 2025
Milestone payment, amount		$ 6,000
Payments for royalities		$ 6,000
Net proceeds from other income			$ 1,000
XOMA [Member]
Assignment and assumption agreement description		Pursuant to the Assignment Agreement, the Company is entitled to receive (i) a one-time payment of $1 million upon acceptance of a re-submission of an NDA to the FDA for arimoclomol, and (ii) a one-time payment of $1 million upon the first invoiced sale in certain territories of a pharmaceutical product derived from arimoclomol as an active pharmaceutical ingredient, subject to the receipt of the applicable regulatory approval required to sell such a product in such countries. In January 2024, the Company received a payment of $1 million in connection with achieving the milestone relating to the acceptance by the FDA of the arimoclomol NDA, and in November 2024, the Company received $1 million in connection with achieving the milestone relating to the first commercial sale of arimoclomol.
Royalty purchase agreement, description	Pursuant to the First Amendment, if the Company decides to commercialize aldoxorubicin itself, prior to the first commercial sale of aldoxorubicin, the Company and XOMA shall enter into a synthetic royalty purchase agreement, pursuant to which the Company shall agree to make quarterly royalty payments to XOMA equal to the amount of all aggregate net sales of aldoxorubicin during each calendar quarter multiplied by 1.5%. If the Company decides not to commercialize aldoxorubicin itself and instead licenses aldoxorubicin to a third party, upon entry of such a new license agreement, XOMA shall be entitled to receive (i) royalty payments with respect to net sales of aldoxorubicin payable to the Company multiplied by 7.5% and (ii) milestone payments of 7.5% of any milestone payable to the Company pursuant to the License Agreement.
Royalty Purchase Agreement [Member]
Payments for royalities		$ 1,000
Aldrorubicin And Arimoclomol [Member]
Legal fees		5,000
Arimoclomol [Member]
Milestone payment, amount				$ 3,650
Commercial sale, amount		1,000
Aldoxorubicin [Member]
Commercial sale, amount		$ 4,000

LadRx Corp 10-Q